Negotiations database

We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.

Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly. 

Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI). 

Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.  

It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.

We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.